| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $123K | -8.4% | — |
| R&D Expense | $1.5M | -25.0% | -16.7% |
| SG&A Expense | $1.8M | +25.7% | +24.6% |
| Operating Income | -$3.4M | +6.3% | -2.2% |
| Net Income | -$3.1M | +7.0% | -6.9% |
| EPS (Basic) | -$0.06 | +14.3% | +0.0% |
| EPS (Diluted) | -$0.06 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $32.6M | -5.0% | -23.0% |
| Accounts Receivable | $0 | -100.0% | — |
| Current Assets | $32.9M | -6.3% | -23.9% |
| Total Assets | $47.6M | -4.5% | -18.1% |
| Current Liabilities | $3.3M | +26.0% | +28.5% |
| Total Liabilities | $3.6M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$7.8M | — | — |
| Capital Expenditures | $3K | — | — |
| Investing Cash Flow | -$3K | — | — |
| Free Cash Flow | -$7.8M | — | — |
| +0.0% |
| +21.8% |
| +18.3% |
| Stockholders' Equity | $44.0M | -6.2% | -20.2% |